# Zevalin-beam for Aggressive Lymphoma

> **NCT00491491** · PHASE3 · COMPLETED · sponsor: **Sheba Medical Center** · enrollment: 60 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** ibritumomab tiuxetan
- **PROCEDURE:** BEAM chemotherapy and autologous stem-cell transplantation

## Key facts

- **NCT ID:** NCT00491491
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-08-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00491491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00491491, "Zevalin-beam for Aggressive Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00491491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*